Theratechnologies: Results of Independent Study on the Effect of Tesamorelin on Cognitive Function Presented at Conference in France

Theratechnologies (NASDAQ: THER) today announced that the results of the independent Somatotrophics, Memory, and Aging Research Trial (SMART) were presented during the 2011 Alzheimer's Association International Conference on Alzheimer's Disease Conference being held July 16-21, in Paris, France. This single-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial was led by Dr. Michael V. Vitiello of the University of Washington in Seattle to evaluate the effect of tesamorelin on cognitive function in healthy older adults and older adults with mild cognitive impairment (MCI), also known as pre-Alzheimer's syndrome. Theratechnologies supplied the tesamorelin for the purposes of this clinical trial. Currently, tesamorelin is not indicated for treatments related to MCI. A total of 152 older adults, half of whom were cognitively normal and half of whom were diagnosed with amnestic MCI, received either tesamorelin or a placebo. Tesamorelin improved executive function (response inhibition, set-shifting, and working memory) in both cognitively normal healthy older adults and in adults with MCI. Tesamorelin also improved delayed verbal recall in adults with MCI.